ARCH Venture Fund XII, L.P. → Neumora Therapeutics, Inc. NMRA

Stake: 18.70% Shares: 33,847,838 CUSIP: 640979100 Class: Common Stock, $0.0001 par value

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

1 13D/G filings on this issuer

0 other filings besides this one

Filer Track Record

2 filings by this filer

1 other filing in the data moat

Short Interest · settle 2026-07-15

DTC 7.56

7,786,397 shares short · +16.5% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $6.58M

Point72 Asset Mgmt

Post-Filing Returns · since 2026-03-30 on NMRA

+1 day

+1.0%

+5 days

+9.8%

+30 days

+16.6%

+60 days

-10.4%

+90 days

-10.4%

+180 days

—

Anchor price 1.93 on closest trading day on/after 2026-03-30. Source: Yahoo Finance daily adj_close (split + dividend adjusted).

Other Filings by ARCH Venture Fund XII, L.P.

Filed	Form	Issuer	Stake	Shares
2025-08-11	SCHEDULE	Prime Medicine, Inc. PRME	10.40%	18,587,036	view →

Want this depth on every filing the moment it hits SEC EDGAR?

Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.

See pricing →